We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Esophageal Cancer Precursor Detected by Electronic Nose Device

By LabMedica International staff writers
Posted on 10 Mar 2020
Barrett's esophagus is a condition in which the lining of the esophagus changes, becoming more like the lining of the small intestine rather than the esophagus. More...
This occurs in the area where the esophagus is joined to the stomach.

The main cause of Barrett's esophagus is thought to be an adaptation to chronic acid exposure from reflux esophagitis. Barrett's esophagus is diagnosed by endoscopy: observing the characteristic appearance of this condition by direct inspection of the lower esophagus; followed by microscopic examination of tissue from the affected area obtained from biopsy.

Gastroenterologists at the Radboud University Medical Center (Nijmegen, the Netherlands) and their colleagues wanted to see how effective and accurate a portable 'electronic nose' device would be for picking up Barrett's esophagus. Some 402 adults scheduled for endoscopy breathed into a highly sensitive electronic nose, designed to detect subtle differences in volatile organic compounds (VOCs) patterns, for five minutes. Of this group, 129 patients had Barrett's esophagus; 141 had acid reflux disease, including 50 who had an inflamed esophagus as a result; and 132 had a normal esophagus or hiatus hernia that accounted for their symptoms.

Analysis of VOCs profiles detected by the electronic nose showed that these differed significantly among patients with Barrett's esophagus, acid reflux, and those with a normal esophagus/hernia. The sensitivity of the device was 91%, its ability to pick up Barrett's esophagus and its specificity was 74%, its ability to detect those without the condition. When the analysis was further restricted to patients who had been taking drugs (proton pump inhibitors) to curb stomach acid production for at least a month or those with a hiatus hernia, both of which are likely to muddy the diagnostic waters, its accuracy was still good.

The authors concluded that the technique analyzing VOCs with an electronic nose may enable an efficient, well-tolerated, and sensitive and specific screening method to select high-risk individuals to undergo upper endoscopy. The study was published on February 25, 2020 in the journal GUT.

Related Links:
Radboud University Medical Center


New
Gold Member
Collection and Transport System
PurSafe Plus®
Portable Electronic Pipette
Mini 96
New
Automatic Chemiluminescence Immunoassay Analyzer
Shine i2000
New
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.